One Call From Tahoe

Last week, while hiking the Tahoe Rim Trail with my 50-pound pack (doctor’s orders), I received a call from a returning Mad Hedge Concierge subscriber who was in a particularly foul mood. Following the advice of another “expert” I won’t mention, he had dumped all his biotech holdings after Vertex’s Q1 earnings miss.

“Aren’t pharmaceutical stocks headed straight to the basement with all this talk about drug price controls?” he asked.

I paused for a moment as a mountain biker weaved across the trail, cutting me off. Then I gave him my response, which I’ll share with you now.

Vertex Pharmaceuticals (VRTX) reported decent Q1 earnings recently, despite falling short of analyst estimates for both revenue and earnings. The stock dropped 4% on the news – a classic overreaction to what was actually a strong underlying report.

As a long-term investor, what matters most isn’t whether a company beats quarterly estimates by a penny or two, but the general direction in which corporate earnings are headed. And Vertex’s trajectory is decidedly upward.

After digesting the Q1 results and updating my earnings model, I project Vertex’s revenue to grow from $11.02 billion in 2024 to approximately $19.32 billion by 2030 – a healthy 75% increase that justifies the stock’s current premium valuation of 28× forward earnings.

Let’s break down how Vertex gets there.

Vertex’s CF drug portfolio is the bedrock upon which the company’s diversification strategy is built.

Alyftrek, which received regulatory clearance late last year, offers notable advantages to CF patients compared to Vertex’s core drugs. For instance, Alyftrek needs to be taken just once daily, compared to other drugs that require twice-daily dosing. This offers much-needed convenience for CF patients, which I believe will drive strong adoption rates.

From a clinical perspective, while Alyftrek hasn’t demonstrated superiority to Trikafta, significant improvements in CFTR function have been noted. With Trikafta patent-protected through 2037, Vertex has ample time to maintain its CF market leadership while diversifying into new markets.

For 2030, I project CF drug revenue of $13.02 billion, representing a modest but reliable 2.5% CAGR. This is deliberately conservative – I’d rather under-promise and over-deliver when it comes to biotech projections.

And Vertex’s growth drivers go beyond their CF pipeline.

Their diversification efforts are most visible in their pain management portfolio. The FDA approval of Journavx for acute pain marks the beginning of a new era for the company.

This is no small market opportunity. The acute pain management market was valued at over $44 billion in 2024.

Being conservative, let’s assume Journavx’s total addressable market is $40 billion, and project the company to secure a 4% share after five full years on the market. This yields $1.6 billion in 2030 revenue.

My estimates are actually pretty modest compared to many Wall Street analysts. Some project Journavx to bring in $2 billion in revenue from acute pain treatment by 2030, but I’ve learned through decades of following biotech that it’s better to be pleasantly surprised than bitterly disappointed.

Vertex also has Suzetrigine for diabetic peripheral neuropathy in Phase 3 studies, with commercialization expected by 2027. If the company secures even a 7% share of this $7 billion market, we’re looking at another $500 million in 2030 revenue.

Overall, I expect the pain management drug portfolio to contribute $2.1 billion in revenue by 2030.

Another promising area is their kidney disease portfolio. Povetacicept, Vertex’s novel treatment for IgA nephropathy, is currently in Phase 3 interim analysis with expected commercialization in 2027. The company plans to target approximately 300,000 IgA nephropathy patients in the U.S. and EU alone.

Assuming Vertex secures a 25% share of this market (valued at approximately $3 billion by 2030), I project $750 million in revenue by 2030. The key advantages here are the lack of significant competition and Povetacicept’s strong clinical profile.

Povetacicept is also in trials for primary membranous nephropathy, with pivotal development beginning later this year. By 2030, I project this indication to add another $200 million in revenue.

I’m also projecting Inaxaplin to obtain regulatory approval for the treatment of APOL1-mediated kidney disease by 2028.

With a target patient count of 250,000 and an annual price of $100,000 (which is conservative for rare disease treatments), if Vertex onboards just 10,000 patients by 2030, that’s another $1 billion in revenue.

From this lineup, I expect Vertex to generate $1.95 billion in revenue in 2030.

Equally impressive is their gene therapy portfolio. Casgevy, Vertex’s gene therapy for sickle cell disease/beta thalassemia, is already being launched globally. With a patient count of around 60,000 in the U.S. and EU alone, I project $1.5 billion in revenue by 2030.

With the potential launch of Zimislecel for Type 1 diabetes in 2027, I estimate an additional $750 million in 2030 revenue, assuming an annual treatment cost of $250,000 with a target of 3,000 patients (out of a total addressable market of 60,000).

Overall, from the gene therapy portfolio, I expect a revenue of approximately $2.25 billion by 2030.

Adding up these various revenue streams, my total revenue estimate for Vertex in 2030 comes to $19.32 billion – marking a 75% increase from 2024.

At an adjusted operating margin of 42.5% (comparable to Q1 2025 and lower than the historical average of over 50%) and an effective tax rate of 21%, Vertex should report net income of $6.42 billion in 2030.

For comparison, in 2024, the company reported a GAAP net loss of $535.6 million (due to one-time charges), but the year before, a net profit of $3.61 billion.

Vertex’s Q1 performance may not have been ideal, but it masks the long-term opportunity facing the company.

There’s no denying the uncertainty associated with the pharmaceutical industry, but I’m convinced Vertex is headed toward substantially higher revenue and earnings by 2030 as its diversification efforts yield results.

Valued at around 28 times next-year earnings, VRTX remains an attractive investment given its category leadership in CF and strategic diversification into several high-growth, niche markets.

That means a $600+ stock price by 2030 is well within reach.

When I finished explaining all this to my disgruntled subscriber, there was a long silence on the other end of the line. Finally, he said, “So you’re telling me I should buy it back?”

“Not yet,” I replied. “Let it settle a bit more. I’ll let you know when.”

With that, I had to hang up as a family of black bears appeared on the trail ahead of me. Some things just can’t wait – like getting out of the way of hungry bears or buying into a pharmaceutical company that’s redefining multiple treatment categories.

Where is a park ranger when you need one?